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HE issues involving the genetic revolution go to the heart of
human dignity. The regulatory approach to genetic engineering in
the German and American systems have been sharply contrasting.
The European Union and Germany, in particular, have displayed a
marked skepticism toward genetic engineering.1 The United States, on
the other hand, has engaged in very little regulation. 2
The United States Constitution does not have a human dignity clause.
The Supreme Court has occasionally tried to add something like this, us-
ing the theory of substantive due process, which is primarily invoked to
support a woman's right to have an abortion. 3 This concept of substan-
tive due process, though controversial, means that the government cannot
take a particular action, regardless of the process it follows, if that action
would undercut fundamental traditions of Anglo-American
jurisprudence. 4
In Saenz v. Roe,5 decided in 1999, the Court tried to revive the much
neglected Privileges and Immunities Clause of the Fourteenth Amend-
ment, which says that the government cannot abridge certain privileges
and immunities that are considered inherent to being a citizen of the
United States. The Saenz case is a rare example of the Court using the
Privileges and Immunities Clause of the Fourteenth Amendment.
No technology in the immediate future will cause more controversy
about the concept of human dignity than genetic engineering, particularly
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1. See Stevan M. Pepa, International Trade and Emerging Genetic Regulatory Re-
gimes, 29 LAW & POL'Y INT'L Bus. 415, 439, 446-47 (1998).
2. See generally Marsha A. Echols, Food Safety Regulation in the European Union
and the United States: Different Cultures, Different Laws, 4 COLUM. J. EUR. L. 525 (1998)
(explaining the markedly different regulatory approaches in the European Union and the
United States).
3. See Anne Lawton, The Frankenstein Controversy: The Constitutionality of a Fed-
eral Ban on Cloning, 87 Ky. L.J. 277, 351 (1999).
4. See, e.g., Palko v. Connecticut, 302 U.S. 319 (1937). Different supreme court opin-
ion express the idea of substantive due process in different ways.
5. 526 U.S. 489 (1999).
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human genetic engineering. Rapid and unimaginable changes are occur-
ring in this area. A few short years ago, the world changed when it dis-
covered that scientists had cloned a sheep named Dolly; that is, they
produced a sheep asexually. Recently scientists have found that the
cloned sheep might age more quickly than the original copy. 6 Whether
this would be true if they cloned an embryo, rather than an adult sheep, is
uncertain. More recently, scientists cloned mice and cows. The mice
were cloned in Japan. 7
There are reports of scientists cloning a human embryo, but not im-
planting it into a woman's womb. 8 For many years now, there have been
discussions about cloning human embryos and developing an exact copy
of each of us, which could be preserved in a frozen state and serve as a
perfect organ donor. After all, the organs would not be rejected and
would be readily available. But what are the ethics of this idea? What
are the implications for human dignity? Does the clone have any rights?
Is she a human being or just a piece of property? Perhaps less problemat-
ically, scientists could clone individual organs using stem cells-cells
which have not yet had the chance to differentiate themselves into spe-
cific uses or organs. 9 About two years ago, scientists isolated stem cells
and got them to grow into neural, gut, muscle, and bone cells.10 While
controversy swirls around the problem that stem cells come from aborted
embryos, scientists are trying to develop alternative sources."1
Separate problems are caused by transgenetic beings. Scientists are al-
ready experimenting with inserting human genes into mice in order to
determine the effect of an isolated human gene causing some kind of dis-
order.' 2 What is the morality of combining human genetic materials with
that of other creatures? Even if one gene or a few genes are acceptable,
what about inserting many genes? What about purposefully creating
transgenetic creatures which have certain human genes and certain ape
genes to make them somewhat more intelligent than apes, and considera-
bly stronger than humans? Suppose these beings were soldiers designed
for war? Even if some countries shun such practices, what about totali-
tarian regimes who might leap at such a prospect? What about the pro-
cess of aging? Scientists may be able to arrest this process by certain
6. See Nic Robertson et al., Scientists: Cloned Sheep Dolly Has "Old" DNA, CNN
INTERACTIVE (visited May 26, 1999) <http://www.cnn.com/nature/9905/26/dolly.clone.02/
index.html>.
7. See David Derbyshire, The Calves Cloned From a Pint of Milk: Made in Japan, the
Latest Breakthrough in Genetic Engineering, DAILY MAIL (London), Apr. 27, 1999, at 19.
8. See Renee C. Esfandiary, The Changing World of Genetics and Abortion: Why the
Women's Movement Should Advocate for Limitations on the Right to Choose in the Area of
Genetic Technology, 4 WM. & MARY J. WOMEN & L. 499, 502 (1998).
9. See Don Knapp, Cell Scientists Hope to Grow Human Spare Parts, CNN INTERAC-
TIVE (visited May 22, 1999) <http://www.cnn.com/health/9905/22/organs.to.grow/>.
10. See Michael D. Lemonick et al., On the Horizon, TIME, Jan. 11, 1999, at 89.
11. See id.
12. See Dan Vergano, Of Transgenic Mice and Men: Human Touch Turns Rodents into
Pioneers of Medical Research, USA TODAY, May 25, 1999, at lD.
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genetic manipulations. 13
Germany and the United States have dramatically different approaches
to the entire arena of genetic engineering. Germany and the European
Community have taken a far more cautious approach, banning foodstuffs
which are the product of genetic engineering. 14 Currently, virtually the
only genetic engineering regulations in the United States concern health
and safety and are promulgated by organizations like the Food and Drug
Administration and the Environmental Protection Agency. 15 There are
also experimentation protocols imposed by the National Institutes of
Health, which are mandatory if government money is used.16
The Supreme Court of the United States has held that genetically
transformed animals are patentable' 7 and the United States Patent Of-
fice, in fact, does grant patents in newly created living organisms. 18 Will
the Patent Office eventually give patents over human beings? What
about the blood that flows in a person's veins? If a hospital uses my
blood to make some new drug, does the hospital have a property right in
that new substance, or do I have a property right because it was my
blood? 19
The most controversial of all genetic technologies is recombinant
DNA, which involves changing the genetic code to create new human
beings.20 Scientists recently completed a complete map of the human
genome, which provides a major step forward to do gene splicing and
other sorts of genetic manipulation.21 Scientists already can perform
some processes whereby they can extract a strand of genetic material
from one being and inject new genetic material in its place. 22 They are
already doing some recombinant DNA to cure diseases.23 This applica-
tion is generally called negative genetic engineering.2 4 More controver-
sial is using recombinant DNA technology to develop such desired traits
as beauty, intelligence, strength, and stamina. This use is sometimes
called positive genetic engineering.2 5 If performed in embryos, such
13. See Lemonick et al., supra note 10.
14. See Bill Hord, Today's High-Tech Harvest Farms and Ranches at the End of the
20th Century Have Evolved into High-Tech Businesses Relying as Much on Computers and
Biogenetics as the Machinery Turning the Soil: Agricultural Milestones, a Century of Agri-
cultural Evolution Glossary, OMAHA WORLD-HERALD, May 24, 1999, at 1.
15. See Curtis A. Kin, Coming Soon to the "Genetic Supermarket" Near You, 48 STAN.
L. REV. 1573, 1580 (1996).
16. See id. at 1578.
17. See Esfandiary, supra note 8, at 504; see also Diamond v. Chakrabarty, 447 U.S.
303 (1980).
18. See Paul Blunt, Selective Breeding and the Patenting of Living Organisms, 48 SYRA-
CUSE L. REV. 1365, 1370 (1998).
19. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).
20. See Kin, supra note 15, at 1581-82.
21. See Brian C. Cunningham, Impact of the Human Genome Project at the Interface
Between Patent and FDA Laws, 7 RIsK: HEALTH SAFETY & ENV'T 253 (1996).
22. See Vergano, supra note 12.
23. See Lemonick et al., supra note 10.
24. See Esfandiary, supra note 8, at 501.
25. See id. at 502.
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processes can affect the germ line and be inheritable, dredging up fright-
ening memories of eugenics. Expense amplifies prospects for master clas-
ses, or indeed races. While such problems particularly infect germ line
manipulations, distributive concerns pervade all of these expensive ge-
netic technologies. Insurance may not cover many of these costly proce-
dures. Indeed, the spotting of adverse genetic traits-such as a
propensity for heart disease-may undercut a particular individual's in-
surability or employability.26
Scientists caution that the possibility of manipulating complex, poly-
genic traits such as intelligence remains far off in the future. However,
developments in this area generally are kept secret, in part, to avoid the
controversy they generate. Developments are also kept secret because
the basic way to protect developments in their early stages is by trade
secrets. The problem with this approach is that the law will play no role
in the discourse if judges and lawyers simply wait until the developments
are upon us. Lawyers must become better trained in science, or technoc-
racy and laissez-faire market mechanisms may supplant the rule of law
and democracy.
Lawyers must also learn to think proactively by mapping out futuristic
scenarios upon which to analyze possible regulatory schemes. Imagine
the following hypothetical: suppose a drug company discovers a new drug
called genos, which can be used to develop stronger, more intelligent
human beings. The method of using the drug involves a series of complex
surgical procedures. Researchers begin by extracting an egg from a wo-
man and fertilizing it in vitro. They proceed through micro-injection to
manipulate pharmacologically the genetic structure of the fertilized egg.
The egg is then inserted back into the uterus where it develops until the
woman gives birth.
Subjects of the genos experiments have been many times stronger-in
both immediate strength and stamina-than the average human being of
their sex, and have had I.Q.s well above genius level. It is undisputed
that the drug is completely safe to use and poses no undesirable side ef-
fects to the mother or to the resulting fetus or child at any stage of devel-
opment. Finally, suppose scarcity of the raw materials necessary to
manufacture the drug will limit genos births to approximately 15,000 per
year. Based on natural scarcity, high production costs, and high surgical
costs, the drug company estimates that the price of having a genos child
will be $370,000. The paucity of raw materials needed to produce genos
will increase the price of the drug for the foreseeable future. Under pres-
sure from citizens who cannot afford the drug, Congress considers the
policy merits and constitutionality of a ban on the manufacture of
26. See John B. Attanasio, The Genetic Revolution: What Lawyers Don't Know, 63
N.Y.U. L. REv. 662 (1988).
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genos. 27
The genos hypothetical holds in tension the foundational, constitutional
ideas of liberty and equality. The basic question must be whether the
United States Constitution affords parental choice to bear children whose
traits are enhanced by positive genetic engineering.
The starting point for addressing this question in America must be the
fundamental right to choose an abortion. Of course, the argument hinges
on the precise scope or breadth of the right guaranteed.2 8 Is it a right to
choose an abortion or a broad right of procreative liberty? In addition,
current American jurisprudence arguably permits considerable genetic
engineering, as for quite some time during the pregnancy, it allows abor-
tion for any reason whatsoever. As science can already spot a number of
undesirable or negative genetic traits, considerable genetic engineering is
already allowed by means of abortion.2 9
On the positive genetic engineering side, science can already spot gen-
der early during pregnancy, which has generated controversy in the U.S.
as some data indicates that couples are opting for male children. 30 As the
vision of science grows more acute, the right to choose an abortion will
increasingly permit parents greater latitude in choosing desirable or posi-
tive genetic traits.
Indeed, the problems sparked by the genos hypothetical are already
upon us. For several years, controversy already has swirled around
growth hormone: who can use it and who pays for it, because it is expen-
sive. At what height is curing an undesirable trait, like shortness, really
negative engineering and at what height does such manipulation become
positive genetic engineering? 31
To regulate genetic engineering, some international consensus must be
achieved. The systems are far apart on these pressing issues, and the eco-
nomic incentives against regulation are large. All of life will be impacted.
Huge fortunes are at stake; and so is all of existence as we have known it.
27. I first presented the genos hypothetical in an article over a decade ago. See John
B. Attanasio, The Constitutionality of Regulating Human Genetic Engineering: Where Pro-
creative Liberty and Equal Opportunity Collide, 53 U. CHI. L. REV. 1274, 1278 (1986).
28. Lawton, supra note 3, at 332.
29. For an extensive discussion of the issues presented by the genos hypothetical, see
Attanasio, supra note 26.
30. See Lee M. Silver, A Quandary that Isn't: Picking a Baby's Sex Won't Lead to
Disaster, TIME, Sept. 21, 1998, at 83; see also Abigail Trafford, Is Sex Selection Wise?,
WASHINGTON POST, Sept. 22, 1998, at Z6.
31. See Kin, supra note 15, at 1573.
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